[go: up one dir, main page]

DK1037917T3 - Rekombinante nodavirus sammensætninger og fremgangsmåder - Google Patents

Rekombinante nodavirus sammensætninger og fremgangsmåder

Info

Publication number
DK1037917T3
DK1037917T3 DK98961962T DK98961962T DK1037917T3 DK 1037917 T3 DK1037917 T3 DK 1037917T3 DK 98961962 T DK98961962 T DK 98961962T DK 98961962 T DK98961962 T DK 98961962T DK 1037917 T3 DK1037917 T3 DK 1037917T3
Authority
DK
Denmark
Prior art keywords
nodavirus
compositions
methods
recombinant
particles
Prior art date
Application number
DK98961962T
Other languages
Danish (da)
English (en)
Inventor
Stephen G Hall
Original Assignee
Scripps Research Inst
Pentamer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Pentamer Pharmaceuticals Inc filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK1037917T3 publication Critical patent/DK1037917T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/30011Nodaviridae
    • C12N2770/30022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/802Virus-based particle
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/882Assembling of separate components, e.g. by attaching
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98961962T 1997-12-08 1998-12-07 Rekombinante nodavirus sammensætninger og fremgangsmåder DK1037917T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/986,659 US6171591B1 (en) 1997-12-08 1997-12-08 Recombinant nodavirus compositions and methods
PCT/US1998/025922 WO1999029723A1 (fr) 1997-12-08 1998-12-07 Compositions de nodavirus recombines et methodes

Publications (1)

Publication Number Publication Date
DK1037917T3 true DK1037917T3 (da) 2007-10-08

Family

ID=25532635

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98961962T DK1037917T3 (da) 1997-12-08 1998-12-07 Rekombinante nodavirus sammensætninger og fremgangsmåder

Country Status (14)

Country Link
US (1) US6171591B1 (fr)
EP (1) EP1037917B1 (fr)
JP (1) JP4503172B2 (fr)
AT (1) ATE366743T1 (fr)
AU (1) AU755201B2 (fr)
BR (1) BR9813416A (fr)
CA (1) CA2313704C (fr)
CY (1) CY1106842T1 (fr)
DE (1) DE69838073T2 (fr)
DK (1) DK1037917T3 (fr)
ES (1) ES2288769T3 (fr)
IL (2) IL136634A0 (fr)
PT (1) PT1037917E (fr)
WO (1) WO1999029723A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637166A3 (fr) * 1998-10-21 2006-04-12 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Particules assimilées à des virus pour l'induction d'auto-anticorps
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
DE60034947T2 (de) * 1999-06-30 2008-01-24 Evotec Ag Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
IL159671A0 (en) * 2001-07-02 2004-06-01 Bioincept Inc New assays for preimplantation factor and preimplantation factor peptides
US8222211B2 (en) * 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
EP1318195A1 (fr) * 2001-12-10 2003-06-11 CatchMabs B.V. Une structure pour la présentation des séquences de peptides désirées
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
WO2004042001A2 (fr) * 2002-05-17 2004-05-21 Emory University Particules pseudovirales, procede de fabrication et compositions immunogeniques
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−aペプチドアナログ−ウイルス様粒子コンジュゲート
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
JP2005272340A (ja) * 2004-03-24 2005-10-06 Japan Science & Technology Agency ノダウイルスの感染予防法および治療法
EP1885394A4 (fr) * 2005-06-01 2009-10-21 Dow Global Technologies Inc Production de particules multivalentes semblables à des virus
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
EP1973608A1 (fr) 2005-12-14 2008-10-01 Cytos Biotechnology AG Particules emballees avec des acides nucleiques immunostimulateurs pour le traitement de l hypersensibilite
EP1835031A1 (fr) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Utilisation d'un virus de la vaccine Ankara modifiée (MVA) recombinant pour le traitement de l'hypersensibilité de type I chez un animal vivant comprenant les humains
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
CA2671873C (fr) 2006-12-12 2018-10-09 Brian Stephen Sproat Oligonucleotides contenant des concentrations elevees en monomeres de guanine
US7998487B2 (en) * 2007-02-16 2011-08-16 The Salk Institute For Biological Studies Antitoxin and vaccine platform based on nodavirus VLPs
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2009055491A2 (fr) * 2007-10-22 2009-04-30 University Of Rochester Vaccin contre le virus syncytial respiratoire basé sur des capsomères ou des particules chimériques semblables au virus du papillomavirus
EP2680872B1 (fr) 2011-03-02 2018-08-15 BioIncept LLC Compositions et procédés pour traiter des lésions intracellulaires
ES2717876T3 (es) 2011-12-12 2019-06-26 Childrens Hospital Philadelphia Sistema de producción de un vector lentiviral a gran escala comercial y vectores así producidos
EP3184639B1 (fr) * 2014-08-21 2019-06-12 Chung-Ang University Industry-Academy Cooperation Foundation Ensemble de cassette d'insertion multiple de gènes à base de rdna nts et souche de levure recombinée de qualité gras
CA2996874A1 (fr) 2015-08-28 2017-03-09 Bioincept, Llc Compositions et methodes pour le traitement d'une lesion neurologique
EP3341739A4 (fr) 2015-08-28 2019-07-10 BioIncept LLC Peptides mutants et procédés de traitement de sujets les employant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4873192A (en) * 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
EP0698666B1 (fr) * 1994-06-21 2006-04-26 Sumitomo Electric Industries, Limited Epimorphine modifiée
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
US5869287A (en) * 1996-07-12 1999-02-09 Wisconsin Alumni Research Foundation Method of producing particles containing nucleic acid sequences in yeast

Also Published As

Publication number Publication date
PT1037917E (pt) 2007-09-19
IL136634A (en) 2007-09-20
EP1037917B1 (fr) 2007-07-11
CA2313704A1 (fr) 1999-06-17
DE69838073T2 (de) 2008-03-20
WO1999029723A1 (fr) 1999-06-17
ES2288769T3 (es) 2008-01-16
US6171591B1 (en) 2001-01-09
ATE366743T1 (de) 2007-08-15
BR9813416A (pt) 2001-10-16
JP4503172B2 (ja) 2010-07-14
CY1106842T1 (el) 2012-05-23
EP1037917A1 (fr) 2000-09-27
AU1714699A (en) 1999-06-28
AU755201B2 (en) 2002-12-05
EP1037917A4 (fr) 2003-02-26
DE69838073D1 (de) 2007-08-23
CA2313704C (fr) 2009-04-07
JP2001525422A (ja) 2001-12-11
IL136634A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
DK1037917T3 (da) Rekombinante nodavirus sammensætninger og fremgangsmåder
ATE327259T1 (de) Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
ATE500323T1 (de) Subtilisin-variante
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
DE3682893D1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
DE60131413D1 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
DE60144021D1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
MY110899A (en) Dengue virus
WO2001057219A3 (fr) Cytokines mammaliennes, leurs recepteurs, reactifs et procedes correspondants
DK0625157T3 (da) Blodplade-GPIIIaP1A1- og -P1A2-epitoper og fremstilling og anvendelse deraf
AP2368A (en) Novel expression vectors and uses thereof.
ATE124420T1 (de) Impfstoffe und testsätze für haemophilus influenzae.
ATE470716T1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
DE60124910D1 (de) Menschliche twik-8 moleküle und ihre verwendung
DK1328621T3 (da) 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf
WO2002051992A3 (fr) 21163, nouvelle propyle oligopeptidase humaine et utilisations correspondantes
DE60136832D1 (de) Atcr-1, eine humane acyltransferase und verwendungen davon
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
ATE435285T1 (de) 14189, eine humane kinase und deren verwendungen
AR003968A1 (es) Peptidos del virus de la arteritis equina, anticuerpos, una composicion para una vacuna, adn y arn recombinante, un plasmido, una celula, antisueros yanticuerpos, un metodo para analizar la presencia o cantidad de anticuerpos y del virus, y un equipo de ensayo